NASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis $67.32 -0.79 (-1.16%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About PROCEPT BioRobotics Stock (NASDAQ:PRCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PROCEPT BioRobotics alerts:Sign Up Key Stats Today's Range$66.54▼$68.1750-Day Range$63.00▼$84.9952-Week Range$24.83▼$85.81Volume500,640 shsAverage Volume600,796 shsMarket Capitalization$3.46 billionP/E RatioN/ADividend YieldN/APrice Target$86.40Consensus RatingBuy Company OverviewPROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. PROCEPT BioRobotics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks79th Percentile Overall ScorePRCT MarketRank™: PROCEPT BioRobotics scored higher than 79% of companies evaluated by MarketBeat, and ranked 226th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingPROCEPT BioRobotics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePROCEPT BioRobotics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PROCEPT BioRobotics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.88) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -32.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -32.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 12.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PROCEPT BioRobotics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.28% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in PROCEPT BioRobotics has recently decreased by 3.16%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.28% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in PROCEPT BioRobotics has recently decreased by 3.16%, indicating that investor sentiment is improving. News and Social Media3.7 / 5News Sentiment0.66 News SentimentPROCEPT BioRobotics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for PROCEPT BioRobotics this week, compared to 4 articles on an average week.Search Interest14 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows11 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,946,415.00 in company stock.Percentage Held by Insiders17.40% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PROCEPT BioRobotics' insider trading history. Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRCT Stock News HeadlinesPROCEPT BioRobotics Co. (NASDAQ:PRCT) CFO Kevin Waters Sells 25,000 SharesOctober 18, 2024 | insidertrades.comPROCEPT BioRobotics Co. (NASDAQ:PRCT) CFO Sells $1,811,750.00 in StockOctober 20, 2024 | americanbankingnews.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Leerink Partnrs Issues Optimistic Forecast for PRCT EarningsOctober 20, 2024 | americanbankingnews.comPROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024October 9, 2024 | globenewswire.comTD Cowen Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)October 9, 2024 | markets.businessinsider.comWhat Analysts Are Saying About PROCEPT BioRobotics StockOctober 9, 2024 | benzinga.comPROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate CancerOctober 7, 2024 | globenewswire.comSee More Headlines PRCT Stock Analysis - Frequently Asked Questions How have PRCT shares performed this year? PROCEPT BioRobotics' stock was trading at $41.91 at the beginning of the year. Since then, PRCT shares have increased by 60.6% and is now trading at $67.32. View the best growth stocks for 2024 here. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Co. (NASDAQ:PRCT) issued its quarterly earnings data on Thursday, August, 1st. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. The business's revenue was up 61.2% on a year-over-year basis. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $126 million in an IPO on Wednesday, September 15th 2021. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? Top institutional shareholders of PROCEPT BioRobotics include Chicago Capital LLC (0.51%), Allspring Global Investments Holdings LLC (0.24%), Essex Investment Management Co. LLC (0.16%) and Taylor Frigon Capital Management LLC (0.14%). Insiders that own company stock include Frederic H Moll, Reza Zadno, Antal Rohit Desai, Morgan Colby Wood, Kevin Waters, Hisham Shiblaq, Alaleh Nouri and Global Investors Lp Viking. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PROCEPT BioRobotics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PROCEPT BioRobotics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA) and Meta Platforms (META). Company Calendar Last Earnings8/01/2024Today10/23/2024Next Earnings (Confirmed)10/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:PRCT CUSIPN/A CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees626Year FoundedN/APrice Target and Rating Average Stock Price Target$86.40 High Stock Price Target$99.00 Low Stock Price Target$69.00 Potential Upside/Downside+28.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,900,000.00 Net Margins-58.73% Pretax Margin-58.74% Return on Equity-37.85% Return on Assets-26.20% Debt Debt-to-Equity Ratio0.20 Current Ratio7.51 Quick Ratio6.49 Sales & Book Value Annual Sales$176.58 million Price / Sales19.61 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book12.11Miscellaneous Outstanding Shares51,424,000Free Float42,896,000Market Cap$3.46 billion OptionableOptionable Beta1.03 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:PRCT) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.